title: Long-term treatment of severe recalcitrant atopic dermatitis with omalizumab, an anti-immuno-globulin E.
authors.forename: Sven R
authors.initials: SR
authors.lastname: Quist
authors.forename: Andreas
authors.initials: A
authors.lastname: Ambach
authors.forename: Daniela
authors.initials: D
authors.lastname: Göppner
authors.forename: Jennifer
authors.initials: J
authors.lastname: Quist
authors.forename: Ingolf
authors.initials: I
authors.lastname: Franke
authors.forename: Bernd
authors.initials: B
authors.lastname: Bonnekoh
authors.forename: Harald P M
authors.initials: HP
authors.lastname: Gollnick
mesh_terms: D018926:Anti-Allergic Agents / Q000008:administration & dosage*; D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D015415:Biomarkers / Q000097:blood; D003876:Dermatitis, Atopic / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D004334:Drug Administration Schedule; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood*; D008297:Male; D008875:Middle Aged; D000069444:Omalizumab; D012008:Recurrence; D012074:Remission Induction; D012720:Severity of Illness Index; D012882:Skin Tests; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D015415:Biomarkers; D000069444:Omalizumab; D007073:Immunoglobulin E